NCT04537910View on ClinicalTrials.gov

A Study of LY3819253 (LY-CoV555) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

December 28, 2020

Study Completion Date

December 28, 2020

Conditions
Healthy
Interventions
DRUG

LY3819253

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

32117

Covance Clinical Research Inc, Daytona Beach

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04537910 - A Study of LY3819253 (LY-CoV555) in Healthy Participants | Biotech Hunter | Biotech Hunter